Tags

Type your tag names separated by a space and hit enter

Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Pharmacotherapy. 2006 Apr; 26(4):469-78.P

Abstract

STUDY OBJECTIVE

To compare, in a usual care setting, the effects of rosuvastatin and other 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) on lipid levels and on goal attainment of low-density lipoprotein cholesterol (LDL) levels from the National Cholesterol Education Program (NCEP) third report of the Adult Treatment Panel (ATP III).

DESIGN

Retrospective, longitudinal, cohort study.

DATA SOURCE

Managed care medical and pharmacy claims and laboratory database.

PATIENTS

A total of 8251 patients starting treatment with rosuvastatin, atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin from August 1, 2003-September 30, 2004, excluding those who received dyslipidemic therapy in the previous 12 months.

MEASUREMENTS AND MAIN RESULTS

Patients with at least one pretreatment and posttreatment lipid level were followed until their initial statin was changed or they reached the end of benefit eligibility or the study period. Percent changes in lipid levels were calculated, and adjusted changes in LDL and goal attainment were evaluated by regression techniques. Absolute and percent reductions in LDL, triglyceride, and total cholesterol levels were significantly greater with rosuvastatin than with other statins (all p<0.05 except for triglyceride reduction vs atorvastatin). After adjustment for age, sex, and baseline LDL, percent LDL reductions still were significantly greater with rosuvastatin than with other statins (p<0.05). Changes in high-density lipoprotein cholesterol were not significant. Goal attainment was higher with rosuvastatin than with other statins after adjustment for age, sex, baseline LDL, risk status, dose, and duration of therapy (p<0.05). Dose-stratified analysis showed that LDL goal attainment was significantly higher with rosuvastatin 10 mg than with atorvastatin 10 or 20 mg.

CONCLUSION

Rosuvastatin was more effective than other statins in reducing LDL, triglyceride (except vs atorvastatin), and total cholesterol levels. Significantly more patients taking rosuvastatin than patients taking other statins attained their LDL goals.

Authors+Show Affiliations

Health Outcomes Research, HealthCore, Inc., Wilmington, Delaware 19801, USA. mbullano@healthcore.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16553504

Citation

Bullano, Michael F., et al. "Effect of Rosuvastatin Compared With Other Statins On Lipid Levels and National Cholesterol Education Program Goal Attainment for Low-density Lipoprotein Cholesterol in a Usual Care Setting." Pharmacotherapy, vol. 26, no. 4, 2006, pp. 469-78.
Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy. 2006;26(4):469-78.
Bullano, M. F., Wertz, D. A., Yang, G. W., Kamat, S., Borok, G. M., Gandhi, S., McDonough, K. L., & Willey, V. J. (2006). Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy, 26(4), 469-78.
Bullano MF, et al. Effect of Rosuvastatin Compared With Other Statins On Lipid Levels and National Cholesterol Education Program Goal Attainment for Low-density Lipoprotein Cholesterol in a Usual Care Setting. Pharmacotherapy. 2006;26(4):469-78. PubMed PMID: 16553504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. AU - Bullano,Michael F, AU - Wertz,Debra A, AU - Yang,Grace W, AU - Kamat,Siddhesh, AU - Borok,Gerald M, AU - Gandhi,Sanjay, AU - McDonough,Kenneth L, AU - Willey,Vincent J, PY - 2006/3/24/pubmed PY - 2006/10/4/medline PY - 2006/3/24/entrez SP - 469 EP - 78 JF - Pharmacotherapy JO - Pharmacotherapy VL - 26 IS - 4 N2 - STUDY OBJECTIVE: To compare, in a usual care setting, the effects of rosuvastatin and other 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) on lipid levels and on goal attainment of low-density lipoprotein cholesterol (LDL) levels from the National Cholesterol Education Program (NCEP) third report of the Adult Treatment Panel (ATP III). DESIGN: Retrospective, longitudinal, cohort study. DATA SOURCE: Managed care medical and pharmacy claims and laboratory database. PATIENTS: A total of 8251 patients starting treatment with rosuvastatin, atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin from August 1, 2003-September 30, 2004, excluding those who received dyslipidemic therapy in the previous 12 months. MEASUREMENTS AND MAIN RESULTS: Patients with at least one pretreatment and posttreatment lipid level were followed until their initial statin was changed or they reached the end of benefit eligibility or the study period. Percent changes in lipid levels were calculated, and adjusted changes in LDL and goal attainment were evaluated by regression techniques. Absolute and percent reductions in LDL, triglyceride, and total cholesterol levels were significantly greater with rosuvastatin than with other statins (all p<0.05 except for triglyceride reduction vs atorvastatin). After adjustment for age, sex, and baseline LDL, percent LDL reductions still were significantly greater with rosuvastatin than with other statins (p<0.05). Changes in high-density lipoprotein cholesterol were not significant. Goal attainment was higher with rosuvastatin than with other statins after adjustment for age, sex, baseline LDL, risk status, dose, and duration of therapy (p<0.05). Dose-stratified analysis showed that LDL goal attainment was significantly higher with rosuvastatin 10 mg than with atorvastatin 10 or 20 mg. CONCLUSION: Rosuvastatin was more effective than other statins in reducing LDL, triglyceride (except vs atorvastatin), and total cholesterol levels. Significantly more patients taking rosuvastatin than patients taking other statins attained their LDL goals. SN - 0277-0008 UR - https://www.unboundmedicine.com/medline/citation/16553504/Effect_of_rosuvastatin_compared_with_other_statins_on_lipid_levels_and_National_Cholesterol_Education_Program_goal_attainment_for_low_density_lipoprotein_cholesterol_in_a_usual_care_setting_ L2 - https://doi.org/10.1592/phco.26.4.469 DB - PRIME DP - Unbound Medicine ER -